Sulfonylureas in today's blood glucose lowering therapy. New data on advantages and potential barriers of an "old" antidiabetic group

Orvosi hetilap
Gábor Winkler

Abstract

Sulfonylurea compounds have been basic elements of antidiabetic treatment in type 2 diabetes for a long time. However, with the introduction of incretin type insulin secretagogues it is often arises, whether is still there a place for sulfonylureas in the today's therapy. To answer this question the author overviews general pharmaceutical characteristics of the sulfonylurea compounds as well as individual particularities of the second generation derivatives used at present in Hungary. The author details also the most important differences between incretin type drugs - first of all dipeptidyl peptidase-4 inhibitors - and sulfonylureas. On the basis of available data it can be concluded in accordance with the latest international guidelines, that sulfonylureas have still role in the blood glucose lowering therapy of type 2 diabetes, though they became somewhat pushed back among insulin secretagogue type drugs. If a sulfonylurea compound is the drug of choice, it is important to select the appropriate molecule (in case of normal renal function gliclazide or glimepiride). It is also important to re-educate the patient, as well as to apply the minimal dose providing the desired glycaemic effect.

References

Sep 27, 2000·Journal of Diabetes and Its Complications·R C O'BrienJ Mercuri
Nov 15, 2000·Metabolism: Clinical and Experimental·A Harrower
Nov 15, 2000·Metabolism: Clinical and Experimental·P E Jennings
Jun 24, 2003·Diabetologia·F M Gribble, F Reimann
Aug 13, 2004·European Journal of Clinical Investigation·G SchernthanerK M Shaw
Apr 25, 2006·Metabolism: Clinical and Experimental·Rury R Holman
Apr 25, 2006·Metabolism: Clinical and Experimental·Stefano Del Prato, Nicolò Pulizzi
Nov 1, 2006·International Journal of Clinical Practice·A Cheng-HakimianJ W Miller
May 15, 2007·The Journal of Pharmacology and Experimental Therapeutics·Marcus WinklerUlrich Quast
Feb 13, 2008·International Journal of Clinical Practice·R ShabsighM Zitzmann
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Jun 12, 2009·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·M MonamiE Mannucci
Feb 23, 2011·Chemistry & Biology·Katie J HerbstJin Zhang
Apr 2, 2011·European Journal of Pharmacology·Lu-Lu ChenHong-cheng Ding
Sep 29, 2011·International Journal of Clinical Practice·S Al SifriUNKNOWN 2010 Ramadan Study Group
Apr 19, 2013·Diabetes, Obesity & Metabolism·M MonamiE Mannucci
Jul 5, 2013·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Alan K L KaiSookja K Chung
Jul 25, 2013·Diabetes·George G HolzColin A Leech
Apr 1, 2014·Orvosi hetilap·Gábor Winkler
Jan 1, 2014·Journal of Clinical Medicine·Yoshifumi Saisho

❮ Previous
Next ❯

Citations

Mar 18, 2017·Statistics in Medicine·Harvey GoldsteinMario Cortina-Borja
Mar 27, 2018·Transactions of the Royal Society of Tropical Medicine and Hygiene·Kriti ThapaElizabeth A Kelvin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.